GLP-1 is not the key mediator of the health benefits of metabolic surgery

Surgery for Obesity and Related Diseases

Volumn 12, Issue 6, 2016, Pages 1225-1229

  Vidal, Josep ^a,b,c   de Hollanda, Ana ^a   Jiménez, Amanda ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Gastric bypass; GLP 1; Metabolic surgery; Sleeve gastrectomy; Type 2 diabetes; Weight loss

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE BLOOD LEVEL;

GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; METABOLISM; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; WEIGHT REDUCTION; ANIMAL; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; GASTRECTOMY; GASTRIC BYPASS SURGERY; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; KNOCKOUT MOUSE; MOUSE; PHYSIOLOGY; PROCEDURES;

ANIMALS; BLOOD GLUCOSE; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GASTRECTOMY; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; WEIGHT LOSS;

EID: 84995377835     PISSN: 15507289     EISSN: 18787533     Source Type: Journal    
DOI: 10.1016/j.soard.2016.02.029     Document Type: Review

References (40)

1. [1] Docherty, N.G., Le Roux, C.W., Physiological adaptations following Roux-en-Y gastric bypass and the identification of targets for bariatric mimetic pharmacotherapy. Curr Opin Pharmacol 25 (2015), 23–29.
2. [2] Seeley, R.J., Chambers, A.P., Sandoval, D.A., The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab 21:3 (2015), 369–378.
3. [3] Dirksen, C., Jorgensen, N.B., Bojsen-Moller, K.N., et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 55:7 (2012), 1890–1901.
4. [4] Patel, R.T., Shukla, A.P., Ahn, S.M., Moreira, M., Rubino, F., Surgical control of obesity and diabetes: the role of intestinal vs. gastric mechanisms in the regulation of body weight and glucose homeostasis. Obesity (Silver Spring) 22:1 (2014), 159–169.
5. [5] Breen, D.M., Rasmussen, B.A., Kokorovic, A., Wang, R., Cheung, G.W., Lam, T.K., Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med 18:6 (2012), 950–955.
6. [6] Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132:6 (2007), 2131–2157.
7. [7] Morinigo, R., Moize, V., Musri, M., et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91:5 (2006), 1735–1740.
8. [8] Rodieux, F., Giusti, V., D׳Alessio, D.A., Suter, M., Tappy, L., Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 16:2 (2008), 298–305.
9. [9] Laferrere, B., Heshka, S., Wang, K., et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:7 (2007), 1709–1716.
10. [10] Laferrere, B., Teixeira, J., McGinty, J., et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93:7 (2008), 2479–2485.
11. [11] Dirksen, C., Hansen, D.L., Madsbad, S., et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care 33:2 (2010), 375–377.
12. [12] Falken, Y., Hellstrom, P.M., Holst, J.J., Naslund, E., Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96:7 (2011), 2227–2235.
13. [13] Dutia, R., Brakoniecki, K., Bunker, P., et al. Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission. Diabetes 63:4 (2014), 1214–1223.
14. [14] Peterli, R., Wolnerhanssen, B., Peters, T., et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 250:2 (2009), 234–241.
15. [15] Valderas, J.P., Irribarra, V., Rubio, L., et al. Effects of sleeve gastrectomy and medical treatment for obesity on glucagon-like peptide 1 levels and glucose homeostasis in non-diabetic subjects. Obes Surg 21:7 (2011), 902–909.
16. [16] Romero, F., Nicolau, J., Flores, L., et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc 26:8 (2012), 2231–2239.
17. [17] Salehi, M., D׳Alessio, D.A., Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery. Rev Endocr Metab Disord 15:3 (2014), 171–179.
18. [18] Salinari, S., le Roux, C.W., Bertuzzi, A., Rubino, F., Mingrone, G., Duodenal-jejunal bypass and jejunectomy improve insulin sensitivity in Goto-Kakizaki diabetic rats without changes in incretins or insulin secretion. Diabetes 63:3 (2014), 1069–1078.
19. [19] LaPierre, M.P., Abraham, M.A., Yue, J.T., Filippi, B.M., Lam, T.K., Glucagon signalling in the dorsal vagal complex is sufficient and necessary for high-protein feeding to regulate glucose homeostasis in vivo. EMBO Rep 16:10 (2015), 1299–1307.
20. [20] Deane, A.M., Nguyen, N.Q., Stevens, J.E., et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 95:1 (2010), 215–221.
21. [21] Nicolaus, M., Brodl, J., Linke, R., Woerle, H.J., Goke, B., Schirra, J., Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 96:1 (2011), 229–236.
22. [22] Woerle, H.J., Carneiro, L., Derani, A., Goke, B., Schirra, J., The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 61:9 (2012), 2349–2358.
23. [23] Jorgensen, N.B., Dirksen, C., Bojsen-Moller, K.N., et al. The exaggerated glucagon-like peptide-1 response is important for the improved beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62:9 (2013), 3044–3052.
24. [24] Vetter, M.L., Wadden, T.A., Teff, K.L., et al. GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification. Diabetes 64:2 (2015), 434–446.
25. [25] Jimenez, A., Casamitjana, R., Viaplana-Masclans, J., Lacy, A., Vidal, J., GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes mellitus after gastric bypass surgery. Diabetes Care 36:7 (2013), 2062–2069.
26. [26] Jiménez, A., Mari, A., Casamitjana, R., Lacy, A., Ferrannini, E., Vidal, J., GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes 63:10 (2014), 3372–3377.
27. [27] Salehi, M., Aulinger, B., Prigeon, R.L., D׳Alessio, D.A., Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes 59:6 (2010), 1330–1337.
28. [28] Jimenez, A., Casamitjana, R., Flores, L., Delgado, S., Lacy, A., Vidal, J., GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects. Ann Surg 257:5 (2013), 894–899.
29. [29] Nannipieri, M., Mari, A., Anselmino, M., et al. The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab 96:9 (2011), E1372–E1379.
30. [30] Holst, J.J., Incretin hormones and the satiation signal. Int J Obes (Lond) 37:9 (2013), 1161–1168.
31. [31] Miras, A.D., le Roux, C.W., Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol 10:10 (2013), 575–584.
32. [32] Le Roux, C.W., Welbourn, R., Werling, M., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246:5 (2007), 780–785.
33. [33] Courcoulas, A.P., Yanovski, S.Z., Bonds, D., et al. Long-term outcomes of bariatric surgery: a National Institutes of Health symposium. JAMA Surg 149:12 (2014), 1323–1329.
34. [34] Dirksen, C., Jørgensen, N.B., Bojsen-Møller, K.N., et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond) 39:5 (2013), 834–841.
35. [35] de Hollanda, A., Jiménez, A., Corcelles, R., Lacy, A.M., Patrascioiu, I., Vidal, J., Gastrointestinal hormones and weight loss response after Roux-en-Y gastric bypass. Surg Obes Relat Dis 10:5 (2014), 814–819.
36. [36] Gerner, T., Johansen, O.E., Olufsen, M., Torjesen, P.A., Tveit, A., The post-prandial pattern of gut hormones is related to magnitude of weight-loss following gastric bypass surgery: a case-control study. Scand J Clin Lab Invest 74:3 (2014), 213–218.
37. [37] de Hollanda, A., Casals, G., Delgado, S., et al. Gastrointestinal hormones and weight loss maintenance following Roux-en-Y Gastric Bypass. J Clin Endocrinol Metab 100:12 (2015), 4677–4684.
38. [38] Chambers, A.P., Jessen, L., Ryan, K.K., et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 141:3 (2011), 950–958.
39. [39] Wilson-Perez, H.E., Chambers, A.P., Ryan, K.K., et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide-1 receptor deficiency. Diabetes 62:7 (2013), 2380–2385.
40. [40] Ye, J., Hao, Z., Mumphrey, M.B., et al. GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am J Physiol Regul Integr Comp Physiol 306:5 (2014), R352–R362.